International Journal of Gynecological Cancer

Papers
(The TQCC of International Journal of Gynecological Cancer is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Inguinofemoral lymphadenectomy technique in 10 steps442
The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization207
The Cukurova score in the prediction of primary cytoreduction in ovarian cancer154
Successful cervical cancer treatment during a monochorionic diamniotic twin pregnancy in a patient with history of preterm delivery105
Well-differentiated papillary mesothelial tumor of the peritoneum92
Complementary use of indocyanine green and technetium to enhance sentinel lymphadenectomy in vulvar cancer86
A population-based study of outcomes in adjuvant radiotherapy for stage II endometrial carcinoma71
Surgical technique and surgeon volume: the pursuit of data-driven outcomes66
Best original research presented at the 25th European Congress on Gynaecological Oncology: best of ESGO 202464
O021/#374 Breast cancer patients are at increased risk of devoleping uterine serous cancer: implication for conseling – a seer analysis63
Authors’ response to: “Methodological concerns regarding AGO score validation in low-grade ovarian cancers”63
22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report60
CERVICAL MELANOMA WITH CEREBRAL DISSEMINATION: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE IN GYNECOLOGIC ONCOLOGY59
HYPOFRACTIONATED RADIATION THERAPY WITH ADAPTIVE PLANNING FOR THE TREATMENT OF ENDOMETRIAL AND CERVICAL CANCER (HERA TRIAL)59
HIDDEN IN PLAIN SIGHT: DESMOPLASTIC SMALL ROUND CELL TUMOUR (DSRCT) PRESENTING AS A GYNAECOLOGICAL MALIGNANCY58
COST-UTILITY ANALYSIS OF A MOLECULAR-INTEGRATED-PROFILE FOR WOMEN WITH (HIGH)INTERMEDIATE RISK ENDOMETRIAL CANCER - PORTEC-4A AN INTERNATIONAL, MULTICENTRE, RANDOMISED, PHASE 3 TRIAL52
INTRA-OPERATIVE COMPLICATIONS OF GYNECOLOGIC ONCOLOGY SURGERIES IN A TEACHING HOSPITAL IN SUB-SAHARAN AFRICA: EXPERIENCE FROM ADDIS ABABA, ETHIOPIA51
LOWER LIMB LYMPHEDEMA AFTER TREATMENT OF CERVICAL CARCINOMA AND ITS IMPACT ON QUALITY OF LIFE49
COLPOSCOPIC-HISTOLOGIC DIAGNOSTIC AGREEMENT IN CERVICAL INTRAEPITHELIAL NEOPLASIA 2+: A FIVE-YEAR REVIEW OF COLPOSCOPIC SERVICES AT THE NATIONAL HOSPITAL ABUJA, NIGERIA COLPOSCOPIC-HISTOLOGIC DIAGNOST48
SIGNIFICANCE & CLINICAL UTILITY OF 2-DEOXY-2-[18F] FLUORO-D-GLUCOSE-POSITRON EMISSION TOMOGRAPHY HIBRID IMAGING IN THE DIAGNOSIS & RESPONSE EVALUATION IN CERVIX CANCER.46
THE LANDSCAPE OF VULVAR CANCER SURVIVAL AND TREATMENT CHARACTERISTICS IN BOTSWANA46
A POTENTIAL BLIND SPOT FOR ANTIBODY–DRUG CONJUGATES TARGETING FOLATE RECEPTOR-146
PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-82645
2022-RA-1495-ESGO Differential metabolism of estrogens in model cell lines and tissues of HGSOC subtypes42
2022-RA-1127-ESGO The efficacy of MEK inhibitors in the treatment of low-grade serous ovarian cancers: a systematic review41
2022-RA-1001-ESGO Analysis of postoperative wound infections in malignancies of the female internal tract40
2022-RA-630-ESGO Overexpression of PDEA1 is a predictive biomarker for platinum resistance and poor prognosis in epithelial ovarian cancer by regulating cell cycle39
2022-RA-981-ESGO Can misdiagnosis be avoided in case of intestinal-type carcinoma of the vagina?A literature comprehensive review39
2022-RA-1690-ESGO Rare uterine cervical adenocarcinomas in salah azaiez institute: clinicopathological features38
2022-RA-1318-ESGO Immunohistochemical profiling of macrophage subtypes in the microenvironment of ovarian tumours in young women37
2022-RA-684-ESGO Factors affecting survival outcomes of patients with clear cell endometrial carcinoma35
2022-RA-1187-ESGO Management and outcomes in high risk GTN – a regional cancer center experience35
2022-RA-1387-ESGO Patients with minimal residual disease at upfront debulking surgery have similar survival outcome than patients with complete cytorreduction after neoadjuvant chemotherapy35
2022-RA-991-ESGO Assessment of high-risk human papillomavirus infections and cervical dysplasia in human immunodeficiency virus-positive pregnant women in germany: a prospective cross-sectional two-ce35
2022-RA-1194-ESGO Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study35
2022-RA-1019-ESGO Endometrial hyperplasia and cancer: results of two reference hospitals in Ankara34
2022-RA-1427-ESGO Fertility outcomes following radical trachelectomy for cervical cancer – a single centre ten year retrospective cohort study33
2022-RA-1272-ESGO Cost-effectiveness of risk-reducing surgery for breast and ovarian cancer prevention: a systematic review32
2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer32
2022-RA-1223-ESGO Cervical cancer in pregnancy: what are the challenges?32
2022-RA-1604-ESGO Efficiency of simulation program for OB/GYN residents using self-training and supervised sessions: a quantitative study31
2022-RA-1191-ESGO Efficacy of a multi-ingredient coriolus versicolor-based vaginal gel in high-risk HPV women over 40: sub-analysis of the paloma clinical trial & papilobs real-life study31
2022-RA-421-ESGO DeflaGyn® has cytotoxic, genotoxic and apoptotic effects on human adenocancer cells: an in vitro study31
2022-RA-1171-ESGO Total vaginectomy for recurrent gynecological cancer. Experience in kazior30
2022-RA-1245-ESGO Correlation between false negatives of FDG-TEP staging in locally advanced cervical cancer and FIGO 2009 clinical staging system. A retrospective single-center cohort30
2022-RA-1635-ESGO Accuracy of MRI imaging in preoperative stage assessment of endometrial cancer in determining extension of surgical procedure29
Primary ovarian leiomyosarcoma: results from an analysis by the French Sarcoma Group (Ovarian SArcoma MAnagement – OSAMA Study)29
Hepatic hilum cytoreductive surgery for ovarian cancer relapse☆29
Correspondence on “Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis” by Zhu and colleagues29
Vulvar cancer resection with V–Y advancement flap reconstruction29
PARSGO and UM6SS: spearheading excellence in gynecological oncology in Morocco29
Pocket guide based on the TNM and FIGO staging systems for classifying patients with locally advanced cervical cancer: a practical tool from the GINECO group for quick and easy management28
Correction: SUCCOR quality: validation of ESGO quality indicators for surgical treatment of cervical cancer28
Role of pre-diagnostic reproductive factors on long-term (10 years or greater) survival of epithelial ovarian cancer: The Extreme study28
Evaluating the use of machine learning in endometrial cancer: a systematic review28
Neoadjuvant chemotherapy with interval debulking surgery in elderly women with advanced ovarian, fallopian tube, or primary peritoneal cancer: real-world evidence from japan27
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)27
Correspondence on “Comparison of the efficacy and safety of five-day methotrexate versus pulse actinomycin D for low-risk gestational trophoblastic neoplasia: a single-center historical cohort study” 27
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation27
Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research a27
Journal Information27
Prognostic impact of low-volume metastatic disease in sentinel lymph nodes of patients with early-stage squamous cell carcinoma of the vulva26
Ovarian reserve in young BRCA mutation carriers: a case-control analysis in reproductive-age women26
Real-world data from the oncosys-OVA clinical trial (NCT06117384) - experiences on genomic and functional HRD testing and molecular determinants of progression during PARP inhibitor treatment26
Epigenetic mechanisms of parpi resistance in ovarian cancer: A systematic review with bioinformatic analysis of clinically actionable genes25
Distribution of molecular subgroups in advanced-stage endometrial cancer: A unicentric retrospective cohort study25
Performance of a generative AI model in assigning FIGO 2023 endometrial cancer stages compared with clinician assessment24
New gynaecological cancer diagnoses in women with a history of breast cancer24
Open label, multicenter, phase 2 study of farletuzumab ecteribulin, a folate receptor alpha-targeting antibody-drug conjugate, alone and in combination with lenvatinib in platinum-resistant ovarian ca24
Step-by-step type C1 robotic radical histerectomy23
Head-to-head comparison between multidisciplinary team and artificial intelligence decision-making in advanced ovarian cancer and predictive accuracy of surgical complexity score: a pragmatic study23
Daphnetin enhances cisplatin chemosensitivity in ovarian cancer by triggering proinflammatory macrophage polarization.23
Mucinous ovarian cancer: A tertiary care centre experience over 10 years23
Impact of controlled ovarian stimulation and oocyte cryopreservation on recurrence and reproductive rates in patients with borderline or malignant ovarian tumours: a retrospective study from a single 23
Association between BRCA1/2 mutation and chemotherapy response score in high grade advanced ovarian cancer: a retrospective cohort study23
Safety of advanced laparoscopic procedures in gynaecologic oncology: a single-centre prospective cohort study22
Evolution of germline and somatic genetic testing in high-grade serous tubo-ovarian carcinoma: A single-centre experience in the czech republic from 2015–202322
Molecular profiling and clinicopathological characteristics of endometrial carcinoma in the kazakh population: first national cohort study (BR24992933)22
Re-irradiation with stereotactic radiotherapy for positive and close margins after pelvic exenteration for recurrent gynaecological cancer22
Awareness of HPV and HPV vaccination in the primary care: A nationwide cross-sectional study22
Evaluating the feasibility of large language models in gynecologic oncology decision-making: A comparative study of chatGPT, google gemini, and bing copilot21
Preoperative risk stratification of p53-abnormal endometrial cancer using expert ultrasound: clinical relevance of nodal staging in a multicentre retrospective study21
Implementation of enhanced recovery after surgery (ERAS) principles in gynecologic oncology: A multi-institutional evaluation from greece21
Ovarian cancer diagnosis within 28 days after an emergency admission to hospital: a national population-based study of patient risk factors and cancer characteristics using routinely collected data in21
The dark side of endometriosis: exploring different atypical and neoplastic transformations21
Clinicopathologic factors associated with recurrence in immature ovarian teratoma: A retrospective institutional study21
Favouring upfront surgery in primary peritoneal cancer: survival impact beyond histology21
Spectrum of molecular subtypes and their clinical associations in endometrial carcinoma: A cohort analysis20
Optimizing sentinel lymph node detection in early-stage ovarian cancer: indocyanine green alone or combined with technetium-99m?20
Impact of the COVID-19 pandemic on service recovery and referral pathways in endometrial cancer care20
A minimally invasive treatment approach for early-stage uterine cervical cancer: the impact of the LACC trial20
Efficacy and safety of dostarlimab plus carboplatin–paclitaxel in first line patients with mismatch repair deficient or microsatellite instability-high recurrent or primary advanced endometrial cancer20
PREVALENCE PATTERN OF HIGH-RISK HUMAN PAPILLOMAVIRUS GENOTYPES IN WOMEN WITH CERVICAL INTRAEPITHELIAL LESIONS IN NORTH MACEDONI20
Acceptability of the EORTC-CX24 quality of life questionnaire in a portuguese sample of cervical cancer treated patients20
Clinical and prognostic impact of the MELF pattern of invasion in endometrioid endometrial carcinoma: A retrospective multivariable evaluation of histopathologic and molecular correlates19
To Compare The Colposcopic Findings By International Federation Of Colposcopy And Cervical Pathology (IFCPC ) Nomenclature And Swede Score For Assessment Of High Grade Cervical Lesions19
Secondary Debulking Followed By Localised Radiotherapy In Patients With Oligometastatic Recurrent Ovarian Cancer – A Case Series Of Two International Cancer Centres19
Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology Registry19
A Multivariable Prognostic Analysis For Survival Outcomes In Women With Epithelial Ovarian Cancer - A North Indian Single Centre Study19
Efficacy of a multi-ingredient coriolus versicolor-based vaginal gel on HR-HPV clearance: final results from the PALOMA 2 clinical trial19
The Role Of Prehabilitation In ERAS For Gynecologic Oncology In Germany19
Evaluating The Implementation And Outcomes Of The Tumor-First Testing Strategy For BRCA1/2 Pathogenic Variants In Ovarian Cancer Patients: A Center-Wide Analysis19
Histological Findings After Completion Hysterectomy And Clinical Outcome Following Conservative Treatment Of Endometrial Carcinoma18
Prospective Multicentre Evaluation Of Secondary Cytoreductive Surgery In The Era Of PARP-Inhibitors (CONCEPT) In Relapsed Epithelial Ovarian Cancer18
Does The Origin Of Ovarian Cancer Influence Outcomes?18
Assessment Of The Predictive Role Of Khorana Score And Genomic Profiling In Ovarian Cancer-Related Venous Thromboembolism18
The Silva Pattern-Based Classification And Oncological Outcomes In Women Undergoing Fertility-Sparing Surgery For Early-Stage Cervical Cancer18
Prognostic Factors In Adult Granulosa Cell Tumours Of The Ovary And Long Term Follow-Up. (The Norwegian Radium Hospital Experience 1971-2024)18
Surgical Release Of The Pudendal Nerve By Robotic Approach In 10 Steps18
Perioperative Outcomes Of Heated Intraperitoneal Chemotherapy For Patients Enrolled In The Feasibility Phase Of A Randomized Controlled Trial: Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy18
SPLEEN PRESERVING EXTENSIVE CYTOREDUCTIVE SURGERY18
Impact Of Ascites And Peritoneal Metastatic Lesion Volumes, Measured By Newly Developed Deep Learning-Based Algorithm, In Advanced Epithelial Ovarian Cancer17
Impact Of Surgery On Survival Outcomes In Locally Advanced Cervical Cancer Patients With Partial Response After Primary Chemoradiotherapy17
Impact Of Preoperative Conization On The Prognosis Of Cervical Cancer Patients Undergoing Open Abdominal Radical Hysterectomy17
Survival Prediction And Mortality Risk Stratification In Ovarian Cancer After NACT: PRGS Outperforms CRS Regression Scoring17
The Prognostic And Predictive Value Of Cardiophrenic Lymph Nodes In Patients Receiving Hyperthermic Intraperitoneal Chemotherapy For Ovarian Cancer In The OVHIPEC-1 Trial17
A fully next-generation sequencing-based method of classifying molecular sub-types of endometrial cancer retains prognostic value and expands biomarker targets17
Excision Of Retroperitoneal Mass - Laparoscopic Management Of Iliac Artery Injury17
A Young Woman Presenting Virilization With Ovarian Mass: A Case Report Of Rare Disease - Ovarian Steroid Tumor16
The “N-PLUS/NOGGO-Ov53/ENGOT-Ov62-STUDY” To De-Escalate Chemotherapy In Ovarian Cancer: Comparing 3 Vs. 6 Cycles Of Platinum-Based Chemotherapy After Complete Tumor Resection Followed By Niraparib Mai16
Surgical Treatment Of Advanced Ovarian Cancer: Experience From A Brazilian Cancer Center (Barretos Cancer Hospital) In 202316
PROGNOSTIC FACTORS BASED ON THE MOLECULAR CLASSIFICATION OF ENDOMETRIAL CANCER: SINGLE INSTITUTION STUDY16
Early-Stage Breast Cancer: A Detailed Examination Of Clinicopathological Features15
Advanced Techniques In Pelvic Exenteration For Cervical Cancer: A Case-Based Surgical Guide15
Computed tomography–based prediction of interval cytoreduction in advanced ovarian cancer15
Squamous Cell Carcinoma Arising In Mature Cystic Teratomas: A Case Series Review Of Presentation, Treatment, And Prognosis15
The Role Of Second-Look Surgery In Recurrent Ovarian Cancer Based On The Type Of Relapse15
Clinical Significance Of Low Volume Lymph Node Metastasis In Early Stage Cervical Cancer: A Single Centre Case Series15
2022-RA-828-ESGO A case of 19 years old, female with malignant spindle cell neoplasm; pelvic monophasic synovial sarcoma arising from the pelvic ligaments15
#840 Neutrophilic inflammation in squamous cell vulvar carcinoma15
Comparative Outcomes Of Excision And Active Surveillance For Cervical Intraepithelial Neoplasia 2 In Women Under 3515
Does Sentinel Node Know The Cancer Origin? Comparing Sentinel Lymph Nodes Localization In Endometrial And Cervical Cancer15
#766 21st century robotic radical hysterectomy should follow strict oncologic principles, have quality control and be nerve-sparring. puppeteer, stapler, bath, dual insufflation, blue and green to the15
#923 PD-1/PD-L1 pathway expression in imiquimod treatment of high-grade cervical lesions15
1173 Diagnostics and treatment of uterine sarcomas: challenges of a low-volume tertiary centre14
461 HBOC and lynch syndrome: ai-powered multi-platform analysis of social media activity14
899 Node-positive carcinoma of vulva treated with curative-intent radiotherapy: reported outcomes from a large single Australian institution14
EP186/#742 Is it time to test all endometrial carcinomas for P53 mutation?14
240 TGF-beta gene polymorphism and ovarian cancer susceptibility14
EV018/#1081  Mapping BTLA immunoreceptor signalling pathways in T-cells14
#305 (R)etrospective (A)nalysis of the correlation of (M)SI-H/DMMR status and response to therapy for (E)ndometrial cancer: RAME study, a multicenter experience14
EP350/#408  Complete visualization of transformation zone in colposcopy using estradiol or misoprostol: a clinical trial14
#909 Fertility -preserving approach in P53 mutant grade 2 endometrioid endometrial canser- cases presentation14
#136 Sentinel lymph node mapping in early-stage ovarian cancer: equivalence of cervix vs utero-ovarian ligament injection for pelvic sentinel lymph node mapping14
EP236/#459  Developing a whole exome sequencing-based homologous recombination deficiency test of epithelial ovarian cancer14
EP268/#152  Exploring the impact of surgical interventions and identifying risk factors for recurrence in borderline ovarian tumors14
398 Prognosis in locally advanced cervical cancer with pelvic lymph node metastases14
#150 E-Cadherin modulates cervical cancer progression by regulating EMT progression via the EGFR signaling pathway13
EV149/#796  Assessment of sentinel lymph node mapping algorithm for staging intermediate to high-risk endometrial cancers13
EP420/#482  Prognostic value of perineural invasion in vulvar cancer13
281 MRI radiomics captures early treatment response in patient-derived organoid endometrial cancer mouse models13
EP281/#1130 Consolidation hyperthermic intraperitoneal chemotherapy in patients with advanced stage ovarian cancer: review of a single center experience13
#393 A rarely seen squamous cell carcinoma arising in the dermoid cyst13
EV420/#706  To evaluate clinical effectiveness, safety and patients experience with apixaban, for extended VTE prophylaxis, after major surgeries for gynaecologic malignancies13
851 Exploring the interplay between the CXCR4 pathway and immune response in serous papillary ovarian tumors13
539 Survival impact of selective lymph node biopsy in patients with early-stage cervical cancer13
EV390/#965  Spectrum of somatic mutations in uterine sarcoma: a single center study13
PR070/#391  Phase I trial of tilvestamab, a function-blocking antibody inhibiting AXL, in platinum-resistant/refractory high grade serous ovarian cancer (PROC)13
506 Consolidation courses in low-risk gestational trophoblastic neoplasia and relapse rate: a MITO-9 study13
EP017/#738  Insights from ovarian cancer patients’ rapid autopsy shed light on mechanisms of CD4+ T cell-mediated pre-metastatic niche formation through the STAT3 axis13
146 Granulosa cell tumors of the ovary: a retrospective study13
EV127/#1083  Is consolidation therapy effective in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment?13
EV402/#953  Barriers to cervical cancer screening in an inner-city obstetrical population: a mixed methods pilot study13
#712 Adjuvant treatment after radical hysterectomy for early cervical cancer13
328 RENI-1: a prospective, multicenter real-world study of niraparib as first-line maintenance therapy in newly diagnosed advanced ovarian cancer13
EP188/#651 Combined nursing and medical quality improvement initiative to incorporate gynaecological oncology tumor board summaries into electronic health records at a tertiary cancer centre in Singap12
#1032 Addressing women’s sexual health after gynecological cancer primary treatment12
#805 An update of a systematic literature review of health state utility values in patients with platinum-resistant or -refractory ovarian cancer12
996 Understanding symptom appraisal and help-seeking in people with symptoms suggestive of endometrial cancer: a mixed methods study12
#597 Possible epigenetic changes that could drive platinum resistance in high grade serous ovarian carcinoma: data from an in-vitro treatment model12
EP002/#234  Results of clinical research (PRUM-IBIO study): establishment of prognostic biomarkers for uterine mesenchymal tumors12
298 Introducing a prehabilitation programme into the care of gynaecological oncology patients – a single institution experience12
EP100/#579  Comparison of oncological outcomes and complication rate between radical hysterectomy and concurrent chemoradiation in stage IIIC cervical cancer without parametrial invasion12
EP179/#1170 High treatment default and low compliance creates ovarian cancer care gap : snapshot annual audit of ovarian cancers at a tertiary centre in a lmic12
EV031/#1651  Clinical characteristics and prognosis of primary mucinous ovarian cancer versus clear cell carcinoma: a 4-year retrospective analysis in Vietnam12
797 Beyond surgery: analysing healthcare professionals satisfaction in eras implementation process12
1310 Clinical and survival associations of arid1a mutations in endometrioid uterine cancer: a TCGA analysis12
908 ‘No-Touch’ intraoperative containment technique in a case of robotic assisted laparoscopic cytoreduction for recurrent ovarian cancer12
1012 Push and pull factors associated with engagement with prehabilitation for ovarian cancer: a qualitative review12
949 Peritoneal carcinoma index (PCI) as a predictor for small bowel resection in advanced ovarian carcinoma surgery12
775 Prevalence and determinants of anemia in cervical cancer patients: a one-year retrospective study11
EP387/#661 Pelvic exenteration in gynecologic cancers: a single center study from India11
PR016/#982  Development and validation of 18F-FDG PET/CT-based models predicting complete cytoreduction during secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer11
#835 Sexual satisfaction after surgery for endometrial cancer: a comparison of the effects of lymphadenectomy on rehabilitation and quality of life. A retrospective analysis at jena university hospita11
PR085/#158  Predictors of lifetime cervical cancer screening and association with social determinants of health: cross-sectional evidence from the Canadian longitudinal study on aging11
722 Imaging-guided preoperative localization of perisplenic isolated local recurrence of ovarian cancer using a combined harpoon and radioactive tracer technique11
304 Exploring mean platelet volume as a survival indicator in ovarian clear cell carcinoma: a retrospective analysis and random forest model assessment11
EP336/#874  Semiquantitative lymphoscintigraphy in gynecologic cancer patients with lower extremity lymphedema: prediction of short-term outcome after lymphaticovenous anastomosis11
11/#620 Oncologic outcome of patients with stage I immature teratoma treated with surveillance or adjuvant chemotherapy11
#733 Choriocarcinoma in young patients after sectio caesarea: a case report11
SF038/#1037 Splenic mobilization and resections in cytoreductive surgery for ovarian cancer11
EP104/#389 Genomic profiling of circulating tumor DNA from peritoneal fluid in endometrial cancer11
347 Risk factors of bone marrow toxicities in ovarian cancer patients treated with parp inhibitors11
EP071/#406 Assessing geographic variation in rates of recurrent or metastatic cervical cancer (based on commencement of systemic therapy) among medicaid enrollees11
803 Efficacy and safety of bevacizumab following prior anti-angiogenic treatment in patients with second-line platinum- based chemotherapy in recurrent ovarian cancer – a subgroup analysis of the AGO-11
EV267/#1245  Enhancing adnexal mass diagnosis: US O-RADS evaluation and clinical correlations11
#328 Frequency and pattern of relapse following adjuvant pelvic radiotherapy or vaginal brachytherapy for high-intermediate risk endometrioid endometrial cancer11
EP397/#844 Survivorship needs of women following treatment for gynaecological cancer – learning from the patient experience to develop future models of care11
1103 Combinatory analysis of CfDNA and CtDNA as a predictive and follow up tool to improve endometrial cancer management11
EV358/#753  Establishing GO Hildas: a diversity-focused co-production group in gynaeoncology to improve health equity11
522 Comparison of efficacy and adverse events of 2 ACT-D regimens in the treatment of low-risk gestational trophoblastic neoplasia: a retrospective study10
362 OPTIMUS: optimising cardiovascular health in endometrial cancer survivors- the impact on quality of life and barriers to change10
SF033/#1181  Instillation of ICG dye into ureters for intra-operative identification during robotic surgery for gynecologic malignancies10
1346 Impact of obesity on sentinel lymph node mapping in patients with endometrial intraepithelial neoplasia undergoing robotic surgery10
668 Clinicopathologic profile of endometrial cancer in Prof. Dr. I.G.N.G Ngoerah general hospital denpasar Bali During the period of January 2022 – october 202310
#72 Ovarian cancer audit of a UK tertiary centre over the past 3 years10
#471 PARP-inhibitors can be applied together with tumor treating fields (TTFields) to prolong survival in an ovarian cancer mouse model10
976 The impact of Covid-19 on the care of endometrial and ovarian cancer: a population-based study in the Netherlands10
SF005/#545  Therapeutic effect of extended pelvic lymphadenectomy in cervical cancer: a propensity-score matched cohort study10
EP260/#796 Robotic primary cytoreductive surgery for advanced stage ovarian cancer: a pilot study, feasibility and outcomes10
1282 Lymph node recurrences in ovarian cancer: safe techniques in the minimally invasive approach10
480 Navigating the uncommon: a twin pregnancy brought to term with complete hydatidiform mole and coexisting fetus10
535 Locally advanced cervical cancer: correlation between pelvic bone radiation dose and acute hematological toxicity10
#1026 Predictors of psychological distress in tunisian women undergoing chemotherapy for gynaecological cancer10
#237 Para vulvar proximal epithelioid sarcoma with yolk sac differentiation: a case report10
EP423/#119  Prognostic factors and clinical outcomes in patients with vulvar cancer: a 15-year retrospective study10
Author index10
FF003/#788 Radical trachelectomy with laterally extended endopelvic resection for locally advanced cervical cancer10
EV457/#362  The psychosocial impact of ovarian cancer: distress, fears and unmet needs10
EP117/#831  Are we underutilizing stereotactic body radiotherapy in the treatment of oligometastatic uterine cancer?10
EP332/#368 Response to systemic therapy in ovarian adult granulosa cell tumors: a literature review9
41/#564 Integrating cervical cancer screening with voluntary family planning in Mozambique: the mulher study9
699 The impact of the bladder volume on the dose to organs at risk dosimetry of vaginal vault brachytherapy9
586 Multicenter real-life data of subsequent chemotherapy after progression to niraparib in a maintenance relapse setting9
Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeins9
EP268/#553 Side effects and decision-making factors associated with maintenance therapy: patient preferences using a visual scale analog (VAS) assessment9
EP378/#781 Advantages of laparoscopy in gynecologic surgery in elderly patients9
227 Differences in clinical pathological features and outcomes in endometrial carcinoma (EC) population in French Overseas: a retrospective study from Martinique, French polynesia (FP) and wallis and 9
EP101/#503 Relevance of genomic instability score, tumor mutational burden, and tumor infiltrating lymphocytes as biomarkers in uterine serous carcinoma9
152 Longitudinal single-cell RNA-seq of ovarian cancer delineates dynamic cellular changes upon hyperthermia9
EV126/#553  Validation of promise NGS; a single-test DNA-based endometrial cancer molecular classifier9
EP259/#509  Genetic counseling and testing for epithelial ovarian cancer in a diverse patient population9
EV210/#1135  Patient satisfaction with clinical nurse specialist led clinic following treatment for a gynaecological malignancy9
#442 Using data mining and data vision to improve the efficiency of a care pathway: an example for advanced adnexal cancers9
Homologous Recombination Deficiency (HRD) In P53 Abnormal Endometrial Carcinoma9
37/#877 Hormonal biomarkers remain prognostic relevant within the molecular classification in endometrial cancer9
EP275/#524 Retrospective analysis of total parietal peritonectomy without systematic lymphadenectomy for advanced epithelial ovarian cancer9
#757 In staging of lymph node positive cervical cancer, the wind in the AJCC was calmed and matched with FIGO staging. FIGO staging is essential, but AJCC’s sound is good9
706 Borderline ovarian tumours: diagnostic and therapeutic difficulties (about 12 cases)9
EP344/#697 Preliminary characterisation of circulating human papillomavirus 16/18/31/35 antibodies for the detection of cervical neoplasia by a rapid point of care test9
#1074 ESGO endometrial cancer quality indicators between ESGO accredited centre in training and comparable centre pursuing for accreditation9
PO005/#134  Risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in real-world ovarian cancer (AOC) patients treated with first- or second-line maintenance PARP inhibitors (PARPI)9
#575 Histological tumor type, sentinel node distribution and involvement in women with early stage cervical cancer – single center experience9
EV290/#1177  Radiological size of the pelvic mass in high-grade serous carcinomas inversely correlates with circulating tumour cell detection from the ovarian vein at surgery9
Letter in response to correspondence on “Comparative analysis of adjuvant treatment outcomes in stage III endometrial cancer: overall survival, recurrence-free survival, site of primary recurrence, an9
EP248/#494 3 years survival and risk of cancer progression and death caused by ovarian cancer in Georgia9
Surgical modality non-inferiority testing with an intensification of adjuvant treatments: a missed opportunity9
EV318/#932  Ovraac: therapeutic impact of eras protocols implementation in cytoreduction surgery for ovarian epithelial cancer9
724 Salpingectomy with delayed oophorectomy versus salpingo-oophorectomy in BRCA1/2 pathogenic variant carriers: three-year results regarding quality of life: an update of the TUBA study9
SF036/#648  Total vaginectomy for reccurent gynecological cancer9
0.21250605583191